Cost-effectiveness of gilteritinib for relapsed/refractory FLT3(mut+) acute myeloid leukemia

BACKGROUND: Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and confirmed feline McDonough sarcoma (FMS)-like tyrosine kinase 3 gene mutations (FLT3(mut+)) have a poor prognosis and limited effective treatment options. Gilteritinib is the first targeted therapy approved in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandya, Bhavik J, Qi, Cynthia Z, Garnham, Andy, Yang, Hongbo, Shah, Manasee V, Zeidan, Amer M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391321/
https://www.ncbi.nlm.nih.gov/pubmed/34595955
http://dx.doi.org/10.18553/jmcp.2021.27.10.1469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391321/
https://www.ncbi.nlm.nih.gov/pubmed/34595955
http://dx.doi.org/10.18553/jmcp.2021.27.10.1469

Ejemplares similares